70 related articles for article (PubMed ID: 16900212)
1. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy.
Lhermitte L; de Labarthe A; Dupret C; Lapillonne H; Millien C; Landman-Parker J; Hermine O; Baruchel A; Sigaux F; Macintyre E; Asnafi V
Leukemia; 2006 Oct; 20(10):1908-10. PubMed ID: 16900212
[No Abstract] [Full Text] [Related]
2. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
[TBL] [Abstract][Full Text] [Related]
3. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
4. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
5. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
6. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
7. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Kucera GL; Klein B; Frankel AE
Bioconjug Chem; 2000; 11(4):564-8. PubMed ID: 10898579
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
10. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
Frankel AE; Ramage J; Kiser M; Alexander R; Kucera G; Miller MS
Protein Eng; 2000 Aug; 13(8):575-81. PubMed ID: 10964987
[TBL] [Abstract][Full Text] [Related]
11. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.
Su Y; Li SY; Ghosh S; Ortiz J; Hogge DE; Frankel AE
Biologicals; 2010 Jan; 38(1):144-9. PubMed ID: 19783458
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
[TBL] [Abstract][Full Text] [Related]
13. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
14. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization.
Potala S; Verma RS
J Biotechnol; 2010 Jul; 148(2-3):147-55. PubMed ID: 20580754
[TBL] [Abstract][Full Text] [Related]
15. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.
Cohen KA; Liu TF; Cline JM; Wagner JD; Hall PD; Frankel AE
Leuk Lymphoma; 2004 Aug; 45(8):1647-56. PubMed ID: 15370220
[TBL] [Abstract][Full Text] [Related]
16. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy.
Hall PD; Sinha D; Frankel AE
Cancer Immunol Immunother; 2006 Aug; 55(8):928-32. PubMed ID: 16645883
[TBL] [Abstract][Full Text] [Related]
17. Phorbol myristate acetate-induced expression of high-affinity interleukin 2 receptors and production of interleukin 2 by human acute lymphoblastic leukemia T cells.
Sahraoui Y; Allouche M; Perrakis M; Clemenceau C; Jasmin C; Georgoulias V
Leukemia; 1992 Apr; 6(4):295-303. PubMed ID: 1588792
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz L; Nomdedéu JF; López O; Carnicer MJ; Bellido M; Aventín A; Brunet S; Sierra J
Haematologica; 2001 Dec; 86(12):1261-9. PubMed ID: 11726317
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
20. Chimeric fusion proteins--diphtheria toxin-based.
Frankel AE; Powell BL; Vallera DA; Neville DM
Curr Opin Investig Drugs; 2001 Sep; 2(9):1294-301. PubMed ID: 11717818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]